galicaftor/navocaftor/ABBV-576 / AbbVie - LARVOL DELTA

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2 | N=48 | Terminated | Sponsor: AbbVie | Active, not recruiting ➔ Terminated; Strategic considerations

Adverse events • Combination therapy • Trial termination • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2 | N=48 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting | N=90 ➔ 48 | Trial completion date: Nov 2023 ➔ Jun 2023 | Trial primary completion date: Oct 2023 ➔ Jun 2023

Adverse events • Combination therapy • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: AbbVie | Active, not recruiting ➔ Recruiting

Adverse events • Combination therapy • Enrollment open • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR

ABBV-576 DDI: A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: AbbVie | Recruiting ➔ Completed | N=60 ➔ 24 | Trial completion date: Apr 2023 ➔ Nov 2022 | Trial primary completion date: Apr 2023 ➔ Nov 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: AbbVie | Trial completion date: Oct 2022 ➔ Nov 2023 | Trial primary completion date: Sep 2022 ➔ Oct 2023

Adverse events • Combination therapy • Trial completion date • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR

ABBV-576 DDI: A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

ABBV-576 DDI: A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: AbbVie

New P1 trial • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases